CytomX Therapeutics, Inc. (CTMX) vs Oculis Holding AG (OCS)
CytomX Therapeutics, Inc. and Oculis Holding AG are both Biotechnology companies. CytomX Therapeutics, Inc. and Oculis Holding AG are of similar size ($599.2M and $579.5M). Oculis Holding AG grew revenue faster over the last twelve months: 65.8% against −87.0%. CytomX Therapeutics, Inc. has the higher net margin (−451.6% vs −6,870.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, CytomX Therapeutics, Inc. leads on 12 and Oculis Holding AG on 3.
Valuation
Profitability
| Metric | CTMX | OCS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (476.19%) | (7,383.66%) | 0.00% |
| Net margin | (451.62%) | (6,870.05%) | 0.00% |
| Free cash flow margin | (450.27%) | (5,525.64%) | 0.00% |
| Return on equity | (39.18%) | (44.87%) | (57.72%) |
| Return on assets | (29.72%) | (37.69%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack